Xenograft Animal Service
New slide

Altogen Labs provides a broad range of CDX, PDX, orthotopic, metastatic, and syngeneic tumor models for biodistribution, PK/PD, efficacy, and imaging studies. Our team helps clients select the most suitable model and study design for their experimental goals. Animal handling and study procedures are conducted under IACUC-approved protocols and applicable GLP standards. Clients receive detailed project reports and experimental data.

Xenograft Animal Service
previous arrow
next arrow

Preclinical Studies: Xenograft (efficacy) and Pharm/Tox (safety)

Altogen Laboratories, located in Austin, TX, is a GLP-compliant laboratory that provides preclinical research services for pharmaceutical, biotechnology, and academic institutions worldwide. Xenograft modeling is our core in vivo expertise: we maintain an extensive and continuously expanding portfolio of in-house validated cell line-derived xenograft (CDX), patient-derived xenograft (PDX), and syngeneic murine models, offered in subcutaneous, orthotopic, disseminated (metastatic), and subrenal capsule formats across nude, SCID, NSG, and NOG hosts, with the SRG rat available for hard-to-engraft tumor types. Our immuno-oncology platform extends this experience to humanized xenografts (hu-PBMC, hu-CD34, and autologous humanized PDX) for the evaluation of immune checkpoint inhibitors, bispecific T-cell engagers, and CAR-T cell therapies, including cytokine release assessment. Our services include safety in vivo toxicology studies (for IND applications), efficacy xenograft studies (for regulatory submissions), drug discovery (patent applications), drug development, and other types of R&D studies including efficacy, PK/PD, safety toxicology, biodistribution, and imaging (BLI/IVIS) studies. Preclinical research studies often require a sequence of experiments utilizing various scientific methods to demonstrate test article efficacy, safety, and mechanism of action. Altogen scientists have many years of experience and expertise that includes all types of nonclinical contract research studies, cell and molecular biology R&D services, pharmacology, and toxicology safety studies that are required for IND. Our in vitro services include 28-day development of stable cell lines, testing compound efficacy and toxicity, gene function and gene expression analysis by qPCR (mRNA) and automated Western Blot system Wes (protein expression), RNAi laboratory services, transient and stable transfections, test compound liposome encapsulation for tissue-targeted delivery, and more.

Technical support and QA/QC teams ensure the company’s high-quality preclinical efficacy and toxicology services. All cell lines are STR-authenticated, PDX models are documented in accordance with the PDX-MI reporting standard, humanized studies follow MISHUM guidance, and in vivo protocols are designed with the OBSERVE and NCI PDXNet consensus recommendations in mind, so your data are ready for publication and regulatory review. We support clients from the study design phase through patent or regulatory submissions (100% of IP belongs to the client). Altogen Labs offers instant quotes, comprehensive service packages, and competitive pricing. We provide a wide range of GLP laboratory services to meet clients’ unique needs, including efficacy studies (xenograft models) and safety studies (pharm/tox), stable cell line development in 28 days, A-to-Z complete RNAi services, anticancer compound testing, liposome encapsulation, cryopreservation, and cell banking services. We are happy to discuss your experimental details to help generate accurate price quotes and timeline estimates (please e-mail study details to info@altogenlabs.com, or call us at 512-433-6177).
Altogen Labs